A retrospective analysis to study the Effectiveness and Safety profile of Remdesivir therapy in patients who diagnosed with COVID-19
Not Applicable
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2021/01/030433
- Lead Sponsor
- Dr Vishal Shanbhag
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All adults patients diagnosed with laboratory-confirmed SARS-CoV-2 infection from March 2020 to September 2020 in Kasturba Hospital Manipal irrespective of gender will be included
Exclusion Criteria
Pediatric population
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Mortality rate/death, Reversal of COVID-19/recovery, Duration of ICU or ventilation and/or Hospital stay, Negative RT-PCR, Improvement in Chest CT, Radiological parameters by CXR Brixia Score, and Lung Zone wise Brixia Score distributionTimepoint: The outcomes will be measured at baseline, at 24 hours, 48 hours, 72 hours, and 5days post administration of remdesivir
- Secondary Outcome Measures
Name Time Method Safety measures such as Adverse events, Serious adverse events, Adverse drug reaction and Treatment discontinuationTimepoint: The outcomes will be measured or monitored at baseline, at 24 hours, 48 hours, 72 hours, and 5days post administration of remdesivir